Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of SHR-2906 injection, a self-developed therapeutic biological product aimed at treating overweight and obesity [1] Group 1: Product Development - SHR-2906 injection is designed to regulate glucose and lipid metabolism, control weight, and improve the metabolic environment in the body [1] - The product is expected to have a synergistic effect in reducing energy intake and promoting energy expenditure [1] - Currently, there are no similar drugs approved for market use domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-2906 injection project has reached approximately 17.06 million yuan [1]